Greenville, NORTH%20CAROLINA3 Active Studies

Sickle Cell Disease Clinical Trials in Greenville, NORTH%20CAROLINA

Find 3 actively recruiting sickle cell disease clinical trials in Greenville, NORTH%20CAROLINA. Connect with local research sites and explore new treatment options.

3
Active Trials
2
Sponsors
501
Enrolling

Recruiting Sickle Cell Disease Studies in Greenville

About Sickle Cell Disease Clinical Trials in Greenville

Sickle cell disease is a group of inherited blood disorders where abnormal hemoglobin causes red blood cells to become rigid and sickle-shaped. It causes pain crises, organ damage, and shortened life expectancy. Treatment includes hydroxyurea, blood transfusions, and gene therapy.

There are currently 3 sickle cell disease clinical trials recruiting participants in Greenville, NORTH%20CAROLINA. These studies are seeking a combined 501 participants. Research is being sponsored by Novartis Pharmaceuticals, Agios Pharmaceuticals, Inc.. Clinical trial participation is free and participants receive study-related medical care at no cost.

Sickle Cell Disease Clinical Trials in Greenville — FAQ

Are there sickle cell disease clinical trials in Greenville?

Yes, there are 3 sickle cell disease clinical trials currently recruiting in Greenville, NORTH%20CAROLINA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Greenville?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Greenville research site will contact you about next steps.

Are clinical trials in Greenville free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Greenville studies also compensate for your time and travel.

What sickle cell disease treatments are being tested?

The 3 active trials in Greenville are testing new therapies including novel drugs, biologics, and treatment approaches for sickle cell disease.

Data updated March 2, 2026 from ClinicalTrials.gov